Fabry disease - A metabolic disorder with a challenge for endocrinologists?

Hormone Research

Volumn 58, Issue 6, 2002, Pages 259-265

  Feldt Rasmussen, Ulla ^a   Rasmussen, A K ^a   Mersebach, H ^a   Rosenberg, K M ^b   Hasholt, L ^b   Sorensen, S A ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GLYCOSPHINGOLIPID;

CLINICAL FEATURE; CLINICAL GENETICS; CLINICAL TRIAL; DRUG TOLERANCE; ENDOCRINOLOGY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FUTUROLOGY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL SPECIALIST; METABOLIC DISORDER; ONSET AGE; PRIORITY JOURNAL; REVIEW; STORAGE DISEASE; TISSUE PRESERVATION; TREATMENT OUTCOME; ENDOCRINE GLAND; GENETICS; GENOTYPE; PATHOPHYSIOLOGY; PHENOTYPE;

AGE OF ONSET; ENDOCRINE GLANDS; FABRY DISEASE; GENOTYPE; HUMANS; PHENOTYPE; TREATMENT OUTCOME;

EID: 0036440370     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066443     Document Type: Review

References (86)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease. N Engl J Med 1967;276:1163-1167.
2. Andersson W: A case of angiokeratoma. Br J Dermatol 1898;10:113-117.
3. Fabry J: Ein beitrag zur kenntnis der purpura haemorrhagica nodularis (purpura papillosa haemorrhagica hebrae). Arch Dermatol Syph 1898;43:187-200.
4. Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254.
5. Desnick RJ, Ioannou AI, Eng CM: α-galactosidase deficiency: Fabry disease; in Schriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Basis of Inherited Disease, Ed 7. New York, McGraw-Hill, 1995, pp 2741-2784.
6. Sweeley CC, Klionsky B: Fabry's disease: Classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963;238:3148-3150.
7. Kint JA: Fabry's disease: α-galactosidase deficiency. Science 1970;167:1268-1269.
8. Desnick RJ, Ioannou AI, Eng CM: α-galactosidase deficiency: Fabry disease; in Schriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds): The Metabolic and Molecular Basis of Inherited Disease, Ed 8. New York, McGraw-Hill, 2001, pp 3733-3774.
9. Kahn P: Anderson-Fabry disease: A histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry 1973;36:1053-1062.
10. Kaye EM, Kolodny EH, Logigian EL, Ullman MD: Nervous system involvement in Fabry disease. Ann Neurol 1988;23:505-509.
11. DeVeber GA, Schwarting GA, Kolodny EH, Kowall NW: Fabry disease: Immunocytochemical characterization of neuronal involvement. Ann Neurol 1992;31:409-415.
12. Seth KJ, Roth DA, Adams MB: Early renal failure in Fabry's disease. Am J Kidney Dis 1983;2:651-654.
13. Becker AE, Schoorl R, Balk AG, Van der Heide RM: Cardiac manifestations of Fabry's disease. Am J Cardiol 1975;36:829-835.
14. Sakuraba H, Yanagawa Y, Igarashi T, Suzuki Y, Suzuki T, Shimoda WK, et al: Cardiovascular manifestations in Fabry's disease. Clin Genet 1986;29:276-283.
15. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH: Cardiac valvular abnormalities in Fabry disease. Clinical, morphologic and biochemical studies. Circulation 1976;54:818-825.
16. Mehta J, Tuna N, Moller JH, Desnick RJ: Electrographic and vector cardiographic abnormalities in Fabry disease. Am Heart J 1977;93:699-705.
17. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Schiffman R: Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-1749.
18. Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, et al: Replacement therapy for inherited enzyme deficiency: Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med 1973;289:9-14.
19. Desnick RJ, Dean KJ, Grabowski GA, Bishop DF, Sweeley CC: Enzyme therapy. XII. Enzyme therapy in Fabry's disease. Proc Natl Acad Sci USA 1979;76:5326-5330.
20. Schiffman R, Murray GJ, Treco D, Daniel P, Sello-Moura M, Myers M, et al: Infusion of α-galactosidase A reduces tissue globotriasylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-370.
21. Schiffman R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al: Enzyme replacement therapy in Fabry disease. A randomised controlled trial. JAMA 2001;285:2743-2749.
22. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance and safety studies. Am J Hum Genet 2001;68:711-722.
23. Eng C, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al: Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
24. Opitz JM, Stiles FC, Wise D, von Gemmingen G, Race RR, Sander R, et al: The genetics of angiokeratoma corporis diffusum (Fabry's disease) and its linkage with Xg(a) locus. Am J Hum Genet 1965;17:325-342.
25. Vetrie D, Bently D, Bobrow M, Harris A: Physical mapping shows close linkage between the α-galactosidase A gene (GLA) and the DXS178 locus. Hum Genet 1993;92:95-99.
26. Kornreich R, Desnick RJ, Bishop DF: Nucleotide sequence of the human α-galactosidase A gene. Nucleic Acids Res 1989;17:3301-3302.
27. Quinn M, Hantzopoulos P, Fidanza V, Calhoun DH: A genomic clone containing the promoter for the gene encoding the human lysosomal enzyme, α-galactosidase A. Gene 1987;58:177-188.
28. pG-rich islands and the function of DNA methylation. Nature 1986;321:209-213.
29. Wise D, Wallace HJ, Jellin EH: Angiokeratoma corporis diffusum. A clinical study of eight affected families. Q J Med 1962;31:177-206.
30. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ: Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 1973;23:871-875.
31. Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT: The vascular dementia of Fabry's disease. Dement Geriatr Cogn Disord 1997;8:252-257.
32. Cable WJ, Kolodny EH, Adams RD: Fabry disease: Impaired autonomic function. Neurology 1982;32:498-502.
33. Argoff CE, Barton NW, Brady RO, Ziessman HA: Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: Response to metoclopramide. Nucl Med Comm 1998;19:887-891.
34. Kang KH, Chun SI, Lee S: Generalised anhidrosis associated with Fabry's disease. J Am Acad Dermatol 1987;17:883-887.
35. Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, et al: The ultrastructrural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 1998;18:109-117.
36. Juul A, Behrenscheer A, Tims T, Nielsen B, Halkjaer-Kristensen J, Skakkebaek NE: Impaired thermoregulation in adults with growth hormone deficiency during heat exposure and exercise. Clin Endocrinol 1993;38:237-244.
37. Sneppen SB, Main KM, Juul A, Pedersen LM, Kristensen LO, Skakkebaek NE, et al: Sweat secretion rates in growth hormone disorders. Clin Endocrinol 2000;53:601-608.
38. Scott LJ, Griffin JW, Luciano C, Barton NW, Banerjee T, Crawford T, et al: Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999;52:1249-1254.
39. Jansen W, Lentner A, Genzel I: Capillary changes in angiokeratoma corporis diffusum. J Dermatol Sci 1994;7:68-70.
40. Idoate MA, Pardo-Mindan FJ, Gonzales-Alamillo C: Fabry's disease without angiokeratomas showing unusual eccrine gland vacuolation. J Pathol 1992;167:65-68.
41. Voglino A, Paradisi M, Dompe G, Muda OA, Faraggiana T: Angiokeratoma corporis diffusum (Fabry's disease) with unusual features in a female patient. Light and electron-microscopic investigation. Am J Dermatopathol 1988;10:343-348.
42. Spaeth GL, Frost P: Fabry's disease. Its ocular manifestations. Arch Ophthalmol 1965;74:760-769.
43. Sher NA, Letson RD, Desnick RJ: The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979;97:671-676.
44. Bloomfield SE, David DS, Rubin AL: Eye findings in the diagnosis of Fabry's disease. Patients with renal failure. JAMA 1978;240:647-649.
45. Sher NA, Reiff W, Letson RD, Desnick RJ: Central retinal artery occlusion complicating Fabry's disease. Arch Ophthalmol 1978;75:491-507.
46. Morgan SH, Rudge P, Smith SJ, Bronstein AM, Kendall BE, Holly E, et al: The neurological complications of Anderson-Fabry disease (α-galactosidase A deficiency) - Investigation of symptomatic or presymptomatic patients. Q J Med 1990;75:491-507.
47. Rosenberg DM, Ferrans VJ, Fulmer JD, Line BR, Barranger JA, Crystal RG: Chronic airflow obstruction in Fabry's disease. Am J Med 1980;68:898-905.
48. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G, et al: Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 1997;155:1004-1010.
49. Mitsias P, Levine SR: Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8-17.
50. Igarashi T, Sakaruta H, Suzuki Y: Activation of platelet function in Fabry's disease. Am J Hematol 1986;22:63-67.
51. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al: Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001;32:1559-1562.
52. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, et al: Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47:229-233.
53. Meroni M, Sessa A, Battini G, Tazzari S, Tarelli TL: Kidney involvement in Anderson-Fabry disease. Contrib Nephrol. Basel, Karger, 1998, vol 19, pp 887-891.
54. Brady RO, Schiffmann R: Clinical features of and recent advances in therapy for Fabry disease. JAMA 2000;284:2771-2775.
55. Gubler M-C, Lenoir C, Grünfeld J-P, Ulmann A, Droz D, Habib R: Early renal changes in hemizygous patients with Fabry's disease. Kidney Int 1978;13:223-235.
56. Pabico RC, Atanacio BC, McKenna BA, Pamukcoglu T, Yodaiken R: Renal pathological lesions and functional alterations in a man with Fabry's disease. Am J Med 1973;55:415-425.
57. Sirvent AE, Enriquez R, Antolin A, Cabezuelo JB, Teruel A, Rodriguez R, et al: Fabry's disease presenting with oligoanuric end-stage renal failure. Nephrol Dial Transplant 1997;12:1503-1505.
58. Ferraus VJ, Hibbs RG, Burda CD: The heart in Fabry's disease. A histochemical and electron microscopic study. Am J Cardiol 1969;24:95-110.
59. Becker AE, Schoorl R, Balk AG, van der Heide RM: Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrographic evidence of myocardial infarction. Am J Cardiol 1975;36:829-835.
60. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ: Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986;7:1157-1161.
61. Von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, et al: An atypical variant of Fabry's disease with manifestations confined in the myocardium. N Engl J Med 1991;324:395-399.
62. Yoshitama T, Nakao S, Takenaka T, Teraguchi H, Sasaki T, Kodama C, et al: Molecular genetic, biochemical and clinical studies in three families with cardiac Fabry's disease. Am J Cardiol 2001;87:71-75.
63. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, et al: Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease: Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A, Pathol Anat Histopathol 1990;417:449-455.
64. Tojo K, Oota M, Honda H, Shibasaki T, Sakai O: Possible thyroidal involvement in a case of Fabry disease. Intern Med 1994;33:172-176.
65. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholin H: Angiokeratoma corporis diffusum: Fabry's disease. Helv Med Acta 1967;34:67-83.
66. Morgan SH, Crawford MA: Anderson-Fabry disease. Br Med J 1988;297:872-873.
67. Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ: Fabry disease: Twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Invest Med 2000;48:227-235.
68. Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litval S, et al: Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001;60:46-51.
69. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293.
70. Lyon MF: Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet 1962;12:135-148.
71. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775.
72. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Brühl K, Gal A, Bunge S, Beck M: Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-724.
73. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W: Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes; α-galactosidase activities in plasma, serum, urine, and leucocytes. J Lab Clin Med 1978;81:157-171.
74. Desnick RJ, Dawson G, Desnick SJ, Sweeley CC, Krivit W: Diagnosis of glycosphingolipidoses by urinary-sediment analysis. N Engl J Med 1971;284:739-744.
75. Rosenberg KM, Schiffmann R, Kaneski C, Brady RO, Sorensen SA, Hasholt L: Five novel mutations in fourteen patients with Fabry disease. Hum Mutat 2000;15:207-208.
76. Hasholt L, Wandall A, Sorensen SA: Enzyme replacement in Fabry endothelial cells and fibroblasts: Uptake experiments and electron microscopical studies. Clin Genet 1988;33:360-371.
77. Abe A, Gregory S, Lee L, Killen PD, Brady RO, Kulkarni A, et al: Reduction of globotriaosyl-ceramide in Fabry disease mice by substrate deprivation. J Clin Invest 2000;105:1563-1571.
78. Abe A, Arend LJ, Lee L, Lingwood C, Brady RO, Shayman JA: Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Kidney Int 2000;57:446-454.
79. Pastores MP, Ravi T: Enzyme replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-603.
80. Kampmann C, Ries M, Bähner F, Kim KS, Bajbouj M, Beck M: Influence of enzyme replacement therapy (ERT) on Anderson Fabry disease associated hypertropic infiltrative cardiomyopathy (HIC). Eur J Pediatr 161:R5.
81. Moore DF, Scott LTC, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Reversal by enzyme replacement therapy. Circulation 2001;104:1506-1512.
82. Peters FP, Sommer A, Vermeulen A, Cheriex EC, Kho TL: Fabry's disease: A multidisciplinary disorder. Postgrad Med J 1997;73:710-712.
83. Jung S-C, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, et al: Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001;98:2676-2681.
84. Takenaka T, Murray G, Qin G, Quirk JM, Ohshima T, Qasba P, et al: Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA 2000;97:7515-7520.
85. Medin JA, Tudor M, Simovitch R, Quirk JM, Jacobson S, Murray GJ, et al: Correction in trans for Fabry disease: Expression, secretion, and uptake of α-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 1996;93:7917-7922.
86. Qin G, Takenada T, Telsch K, Kelley L, Howard T, Levade T, et al: Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 2001;98:3428-3433.